Genentech, Inc.-Product Pipeline Review-2015

Genentech, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06783CDB
  • |
  • Pages: 119
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Genentech, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Genentech, Inc.-Product Pipeline Review-2015', provides an overview of the Genentech, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genentech, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Genentech, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Genentech, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Genentech, Inc.'s pipeline products

Reasons To Buy

Evaluate Genentech, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Genentech, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Genentech, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Genentech, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genentech, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Genentech, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Genentech, Inc. Snapshot 6

Genentech, Inc. Overview 6

Key Information 6

Key Facts 6

Genentech, Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Genentech, Inc.-Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products-Monotherapy 13

Pipeline Products-Partnered Products 14

Pipeline Products-Out-Licensed Products 16

Genentech, Inc.-Pipeline Products Glance 18

Genentech, Inc.-Late Stage Pipeline Products 18

Genentech, Inc.-Clinical Stage Pipeline Products 19

Genentech, Inc.-Early Stage Pipeline Products 21

Genentech, Inc.-Drug Profiles 24

etrolizumab 24

lampalizumab 26

taselisib 28

crenezumab 30

duligotuzumab 32

ipatasertib 34

lifastuzumab vedotin 36

pictilisib 38

polatuzumab vedotin 40

quilizumab 42

RG-6046 44

RG-7652 45

RG-7745 46

DLYE-5953A 47

DMUC-4064A 48

RG-6047 49

RG-7450 50

RG-7741 51

RG-7841 52

RG-7842 53

RG-7882 54

RG-7888 55

RG-7893 56

BV-6 57

CS-3 59

G007-LK 60

G244-LM 61

GNE-293 62

GNE-317 63

GNE-3511 64

GNE-7915 65

GNE-892 66

MAb-30D8 67

Monoclonal Antibody Conjugate for Cancer 68

Monoclonal Antibody to Inhibit Tau for Alzheimer's Disease 69

MV-1 70

Small Molecule to Inhibit BACE1 for Alzheimer's Disease 71

Small Molecule to Inhibit MAP4K4 for Cancer 72

Small Molecule to Inhibit PI3K for Cancer 73

Small Molecule to Inhibit TYK2 for Psoriasis and IBD 74

Small Molecules to Inhibit JAK2 for Cancer 75

Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms 76

Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma 77

Small Molecules to Inhibit Mammalian Rapamycin Kinase for Prostate Cancer 78

Small Molecules to Inhibit NAMPT for Cancer 79

Small Molecules to Inhibit PI3-Kinase Delta for Inflammatory and Leukocyte Disorders 80

Monoclonal Antibody Conjugated for Cancer 81

Small Molecule 2 for Undisclosed Indication 82

Small Molecule to Inhibit ITK for Allergic Asthma 83

Small Molecules 1 for Undisclosed Indication 84

Small Molecules for Bacterial Infections 85

Small Molecules for Central Nervous System Disorders 86

Small Molecules for Undisclosed Indication 87

Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation 88

Small Molecules to Inhibit Jak1/2 for Hematopoietic and Immunologic diseases 89

Small molecules to Inhibit Pim Kinase for Multiple Myeloma 90

Genentech, Inc.-Pipeline Analysis 91

Genentech, Inc.-Pipeline Products by Target 91

Genentech, Inc.-Pipeline Products by Route of Administration 93

Genentech, Inc.-Pipeline Products by Molecule Type 94

Genentech, Inc.-Pipeline Products by Mechanism of Action 95

Genentech, Inc.-Recent Pipeline Updates 97

Genentech, Inc.-Dormant Projects 104

Genentech, Inc.-Discontinued Pipeline Products 105

Discontinued Pipeline Product Profiles 106

Genentech, Inc.-Company Statement 111

Genentech, Inc.-Locations And Subsidiaries 112

Head Office 112

Other Locations & Subsidiaries 112

Genentech, Inc.-Key Manufacturing Facilities 113

Appendix 114

Methodology 114

Coverage 114

Secondary Research 114

Primary Research 114

Expert Panel Validation 114

Contact Us 114

Disclaimer 115

List of Tables

Genentech, Inc., Key Information 10

Genentech, Inc., Key Facts 10

Genentech, Inc.-Pipeline by Indication, 2015 12

Genentech, Inc.-Pipeline by Stage of Development, 2015 16

Genentech, Inc.-Monotherapy Products in Pipeline, 2015 17

Genentech, Inc.-Partnered Products in Pipeline, 2015 18

Genentech, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 19

Genentech, Inc.-Out-Licensed Products in Pipeline, 2015 20

Genentech, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 21

Genentech, Inc.-Phase III, 2015 22

Genentech, Inc.-Phase II, 2015 23

Genentech, Inc.-Phase I, 2015 24

Genentech, Inc.-Preclinical, 2015 25

Genentech, Inc.-Discovery, 2015 27

Genentech, Inc.-Pipeline by Target, 2015 95

Genentech, Inc.-Pipeline by Route of Administration, 2015 97

Genentech, Inc.-Pipeline by Molecule Type, 2015 98

Genentech, Inc.-Pipeline Products by Mechanism of Action, 2015 99

Genentech, Inc.-Recent Pipeline Updates, 2015 101

Genentech, Inc.-Dormant Developmental Projects,2015 108

Genentech, Inc.-Discontinued Pipeline Products, 2015 109

Genentech, Inc., Other Locations 116

Genentech, Inc., Subsidiaries 116

Genentech, Inc., Key Manufacturing Facilities 117

List of Figures

Genentech, Inc.-Pipeline by Top 10 Indication, 2015 12

Genentech, Inc.-Pipeline by Stage of Development, 2015 16

Genentech, Inc.-Monotherapy Products in Pipeline, 2015 17

Genentech, Inc.-Partnered Products in Pipeline, 2015 18

Genentech, Inc.-Out-Licensed Products in Pipeline, 2015 20

Genentech, Inc.-Pipeline by Top 10 Target, 2015 95

Genentech, Inc.-Pipeline by Top 10 Route of Administration, 2015 97

Genentech, Inc.-Pipeline by Top 10 Molecule Type, 2015 98

Genentech, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 99

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Genentech, Inc.; Genentech, Inc. - Key Therapeutics; Genentech, Inc. - Pipeline Overview and Promising Molecules; Genentech, Inc. - News; Genentech, Inc. - Latest Updates; Genentech, Inc. - Pipeline; Genentech, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 100380
Site License
USD 3000 INR 200760
Corporate User License
USD 4500 INR 301140



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]